Search





Search





Markets
/
Stocks
/
xrtx
/

XORTX Therapeutics Inc

XRTX

Add to Watchlist

2.120USD

+0.100+4.95%

Close 07-31 16:00（ET）Quotes delayed by 15 min

2.95MMarket Cap

LossP/E TTM

XORTX Therapeutics Inc

2.120

+0.100+4.95%

Overview

Financials

Discussions

Analysis

Company

View Detailed Chart

TradingKey Chart

Intraday

30m

Today

+4.95%

5 Days

+4.69%

1 Month

-2.30%

6 Months

-15.12%

Year to Date

-24.56%

1 Year

-41.32%

Key Figures

2.010Open

2.150High

7.34KVolume

LossP/E TTM

--P/E Dynamic

--Dividend TTM

0.53%Turnover Ratio

2.020Prev. Close

2.010Low

9.93KTurnover

LossP/E Static

2.30P/B

0.00%Div Yield TTM

-98.03%ROA

9.85052wk High

0.34Volume Ratio

-3.31MNet Profit

1.39MShares

-4.7735EPS TTM

0.17Beta

-137.44%ROE

2.42552wk Low

6.93%Amplitude

--Gross Margin

2.95MMarket Cap

-0.45Reward/Risk

5.36%Risk Rate

XORTX Therapeutics Inc News

More news coming soon, stay tuned...

Earnings Forecast

Analyst Rating

Based on 1 analysts

Buy

Current Rating

70.000

Target Price

+2943.48%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

496

Total

Median

Average

Company name

Ratings

Analysts

XORTX Therapeutics Inc

XRTX

Beigene Ltd

ONC

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

Insmed Inc

INSM

...

Indicators

Indicators

Sell(1)

Neutral(2)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

0.025

Neutral

RSI(14)

52.519

Neutral

STOCH(KDJ)(9,3,3)

57.898

Buy

ATR(14)

0.104

Low Volatility

CCI(14)

140.502

Buy

Williams %R

22.727

Buy

TRIX(12,20)

-0.218

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

2.054

Buy

MA10

2.045

Buy

MA20

2.054

Buy

MA50

2.146

Sell

MA100

2.258

Sell

MA200

2.544

Sell

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

XORTX Therapeutics Inc. is a pharmaceutical company. The Company is engaged in developing medications that improve the quality of life and health of individuals with gout and other important diseases. It has three clinically advanced products in development: its lead program, XRx-026 program for the treatment of gout; XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD); and XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type II diabetic nephropathy. It is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. The XRx-026 program is designed to decrease the chronically high serum uric acid concentration in the blood (SUA) by inhibiting the production of uric acid by the xanthine oxidase enzyme by administering a xanthine oxidase inhibitor-oxypurinol.

Ticker SymbolXRTX

CompanyXORTX Therapeutics Inc

CEODavidoff (Allen W)

Websitehttps://www.xortx.com/